These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37122579)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.
    Javidnia M; Frasier M; Shoulson I; Turkoz I; Budur K
    Innov Clin Neurosci; 2020 Jan; 17(1-3):14-19. PubMed ID: 32547841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric residency training in an era of managed care: an introduction to proceedings of a national conference.
    Finkelstein JA
    Pediatrics; 1998 Apr; 101(4 Pt 2):735-8. PubMed ID: 9544176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.
    Szabo ST; Kinon BJ; Brannan SK; Krystal AK; van Gerven JM; Mahableshwarkar A; Sachs GS
    Innov Clin Neurosci; 2015; 12(3-4):11S-25S. PubMed ID: 25977837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative Technologies in CNS Trials: Promises and Pitfalls for Recruitment, Retention, and Representativeness.
    Lutz J; Pratap A; Lenze EJ; Bestha D; Lipschitz JM; Karantzoulis S; Vaidyanathan U; Robin J; Horan W; Brannan S; Mittoux A; Davis MC; Lakhan SE; Keefe R
    Innov Clin Neurosci; 2023; 20(7-9):40-46. PubMed ID: 37817816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.
    Goldstein B; Giroir B; Randolph A;
    Pediatr Crit Care Med; 2005 Jan; 6(1):2-8. PubMed ID: 15636651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
    Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
    Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to special issue: moving forward in pediatric neuropsychology.
    Daly BP; Giovannetti T; Zabel TA; Chute DL
    Clin Neuropsychol; 2011 Aug; 25(6):897-902. PubMed ID: 21955109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Special Panel Session: Driving Critical Initiatives in Motor Speech.
    Weismer G; Barlow S; Smith A; Caviness J
    J Med Speech Lang Pathol; 2008; 16(4):283. PubMed ID: 19421339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the quality of healthcare provided to children.
    Mangione-Smith R; McGlynn EA
    Health Serv Res; 1998 Oct; 33(4 Pt 2):1059-90. PubMed ID: 9776949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology.
    Grabb MC; Gobburu JVS
    Prog Neurobiol; 2017 May; 152():38-57. PubMed ID: 27216638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical conferences for physicians: Who sets the agenda?
    Abakumova TR; Safina AF; Ziganshina LE
    Int J Risk Saf Med; 2015; 27 Suppl 1():S91-2. PubMed ID: 26639730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the experience with pediatric written requests issued for oncology drug products.
    Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.
    Falls KC; Sharma RA; Lawrence YR; Amos RA; Advani SJ; Ahmed MM; Vikram B; Coleman CN; Prasanna PG
    Radiat Res; 2018 Oct; 190(4):350-360. PubMed ID: 30280985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.